What is the BiotechSign catalyst score for KPTI?

KPTI has a latest available BiotechSign catalyst score of 39/100 and grade D. The score model uses available FDA, clinical-trial, insider, dilution, sentiment, short-interest, and source-backed signal overlap records.

What signals does BiotechSign track for KPTI?

BiotechSign tracks available signal categories and recent signal records for KPTI, including FDA-event, insider, clinical-trial, short-interest, dilution, and source-backed publication signals when available.

When was the KPTI catalyst page updated?

This KPTI page was refreshed from BiotechSign data on 2026-08-17.

← Back to Screener

KPTI — Karyopharm Therapeutics

Karyopharm Therapeutics

OncologyScore: 39/10050 Signal RecordsFull Profile

What is the current KPTI catalyst setup?

KPTI is tracked by BiotechSign with a latest available catalyst score of 39/100 and grade D. The page summarizes available signal categories and recent signal records, including FDA-event, insider, clinical-trial, short-interest, dilution, and source-backed publication signals when available, with data refreshed on 2026-08-17.

Factual Company SnapshotUpdated 2026-08-17

As of 2026-08-17, Karyopharm Therapeutics (KPTI) has a BiotechSign Catalyst Score of 39/100, rated D. BiotechSign tracks available signal categories and recent signal records for this company. The BiotechSign score model uses available FDA-event records, clinical-trial activity, SEC insider filings, dilution-risk records, and sentiment inputs to calculate a catalyst grade.

Scope note: this signal page is not a complete drug pipeline, approved-product portfolio, FDA approval history, investigation history, or regulatory-event profile. It only renders the verified signal records currently mapped in BiotechSign.

This page displays automatically assembled records from BiotechSign data sources and may contain source-data errors or omissions. It is for informational purposes only, not financial advice, not medical advice, and not an investment recommendation. Do your own research and review the full disclaimer and terms of service.

Verified Factual Summary

Verified 2026-08-15

Karyopharm Therapeutics (KPTI) is the lead sponsor of 8 active clinical trials listed on ClinicalTrials.gov^[3], including 3 Phase 3^[1], 5 Phase 2^[2].

Trial NCT05611931^[4] evaluates Selinexor in Endometrial Cancer with a target enrollment of 257 participants. Trial NCT04562389^[5] evaluates Selinexor in Myelofibrosis with a target enrollment of 353 participants. Trial NCT04442022^[6] evaluates Selinexor (combination therapy) in Relapsed/Refractory Diffuse Large B-cell Lymphoma with a target enrollment of 501 participants.

KPTI has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[7].

Sources

ClinicalTrials.gov (2026-08-15) ↗
ClinicalTrials.gov (2026-08-15) ↗
ClinicalTrials.gov (2026-08-15) ↗
ClinicalTrials.gov · NCT05611931 (2026-05-29) ↗
ClinicalTrials.gov · NCT04562389 (2026-04-09) ↗
ClinicalTrials.gov · NCT04442022 (2026-07-02) ↗
SEC EDGAR · 0001503802 (2026-08-15) ↗

This verified summary is automatically assembled from sourced records. It is not financial advice, medical advice, or an investment recommendation. Do your own research and read the full disclaimer and terms of service.

DILUTION

Score: 68/100 (HIGH)

↗

Signal Summary

PDUFA0

Insider0

Clinical0

Data Sources

Dilution◌ LOADING

SEC EDGAR● LIVE

ClinicalTrials● LIVE

Yahoo Finance● LIVE